A Prospective, Open label, Single arm, Multi-centric, Investigator initiated study (IIS) for evaluation of efficacy and safety of Levonadifloxacin (IV And Oral) in patients of Community Acquired Bacterial Pneumonia (CABP).

Dr B P Singh0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Adult subjects with 18 years and above of age
•2. Subjects must be willing to participate in the study and provide a written informed consent
•3. Patient diagnosed with Community Acquired Bacterial Pneumonia (CABP) and to be treated with Levonadifloxacin (IV or Oral) as per investigatorÃ¢â?¬•s discretion

•1.Subjects with history of hypersensitivity to any of the study drugs or same class of drugs
•2.Subjects who received any experimental drug within 30 days prior to enrolment
•3.Subjects who, in the judgment of the Investigator, are likely to be noncompliant or uncooperative during the study
•4.Subjects with any abnormality that the Investigator deems to be clinically relevant, either on medical history, systemic examination or ECG

发起方

Dr B P Singh